Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other analysts have also commented on ENLV. HC Wainwright lifted their target price on Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $13.00.

Enlivex Therapeutics Stock Down 3.7%

Shares of NASDAQ ENLV opened at $1.05 on Friday. Enlivex Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.10. The firm has a market cap of $249.25 million, a P/E ratio of -1.91 and a beta of 1.55. The company has a 50 day moving average of $1.10 and a 200 day moving average of $1.02.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENLV. Citizens Financial Group Inc. RI bought a new stake in Enlivex Therapeutics in the 3rd quarter worth approximately $241,000. Renaissance Technologies LLC lifted its holdings in shares of Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after buying an additional 156,336 shares during the period. HRT Financial LP boosted its stake in shares of Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after buying an additional 135,198 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after buying an additional 67,886 shares during the last quarter. Finally, Invesco Ltd. bought a new stake in shares of Enlivex Therapeutics in the fourth quarter worth $43,000. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.